key: cord-0979444-cvizh741
authors: Bouch, Sheena; Litvack, Michael L.; Litman, Kymberly; Luo, Lisha; Post, Alex; Williston, Emma; Park, Amber J.; Roach, Elyse J.; Berezuk, Alison M.; Khursigara, Cezar M.; Post, Martin
title: Therapeutic stem cell‐derived alveolar‐like macrophages display bactericidal effects and resolve Pseudomonas aeruginosa‐induced lung injury
date: 2022-04-20
journal: J Cell Mol Med
DOI: 10.1111/jcmm.17324
sha: 521a8808cdabead6d1833ab85202a4fb289cb494
doc_id: 979444
cord_uid: cvizh741

Bacterial lung infections lead to greater than 4 million deaths per year with antibiotic treatments driving an increase in antibiotic resistance and a need to establish new therapeutic approaches. Recently, we have generated mouse and rat stem cell‐derived alveolar‐like macrophages (ALMs), which like primary alveolar macrophages (1'AMs), phagocytose bacteria and promote airway repair. Our aim was to further characterize ALMs and determine their bactericidal capabilities. The characterization of ALMs showed that they share known 1'AM cell surface markers, but unlike 1'AMs are highly proliferative in vitro. ALMs effectively phagocytose and kill laboratory strains of P. aeruginosa (P.A.), E. coli (E.C.) and S. aureus, and clinical strains of P.A. In vivo, ALMs remain viable, adapt additional features of native 1'AMs, but proliferation is reduced. Mouse ALMs phagocytose P.A. and E.C. and rat ALMs phagocytose and kill P.A. within the lung 24 h post‐instillation. In a pre‐clinical model of P.A.‐induced lung injury, rat ALM administration mitigated weight loss and resolved lung injury observed seven days post‐instillation. Collectively, ALMs attenuate pulmonary bacterial infections and promote airway repair. ALMs could be utilized as an alternative or adjuvant therapy where current treatments are ineffective against antibiotic‐resistant bacteria or to enhance routine antibiotic delivery.

susceptible to bacterial lung infections. [2] [3] [4] [5] Furthermore, in light of the SARS-CoV-2 pandemic, in developed countries ~8% of critically ill SARS-CoV-2 patients present with bacterial co-infections and antimicrobial therapies are routinely administered as a prophylactic measure, 6, 7 potentially leading to a further increase in antibiotic resistance in our rapidly evolving healthcare landscape. 8, 9 Recently, the World Health Organization published a list of 12 multi-antibioticresistant priority pathogens that pose the greatest threat to global human health; four of these directly colonize the lungs, namely

Pseudomonas aeruginosa (P.A.), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumonia, and Haemophilus influenzae. 10, 11 Current trends suggest that traditional antibiotic therapy is becoming less effective in clearing infections, resulting in longer hospital visits, higher medical costs and increased mortality. 8 Thus, innovative approaches for new therapies need to be developed to combat antibiotic resistance. Cell-based therapies hold promise as a revolutionary therapeutic to treat respiratory infections and halt global antibiotic resistance.

Primary alveolar macrophages (1'AMs) are tissue-resident macrophages of the pulmonary innate immune system that maintain healthy airways by orchestrating the clearance pathogens and initiating an adaptive immune response. 12, 13 Unlike bone marrowderived Myb + macrophages, which arise from adult hematopoietic stem cells, Myb − 1'AMs are from embryonic or foetal origin and self-replicate, making them an ideal candidate for cell-based therapies. [14] [15] [16] In recent years, we have developed novel alveolarlike macrophages (ALMs) that are derived from pluripotent stem cells (PSCs) and retain key embryonic signatures of Myb − 1'AMs. 17 Previously, we have demonstrated that ALMs reduce lung injury in mouse models of acute and chronic lung diseases, can internalize dead Staphylococcus aureus (S.A.) 17 and kill respiratory syncytial virus (RSV) and prevent RSV-induced lung injury. 18 Here, we further characterized ALMs for their efficacy to treat bacterial lung infections. We evaluated the non-pharmacological antimicrobial functions of ALMs, specifically for bacteria known to colonize the lungs of immune-compromised individuals, such as P.A. and S.A. in CF patients, and Escherichia coli (E.C.) that is nosocomially acquired in many pneumonia patients. Lastly, we also illustrate ALMs ability to resolve P.A.-induced lung injury in a preclinical model.

ALMs were differentiated from mouse (G4 DsRed-MST) and rat (DAc8) PSC lines and cultured in macrophage media as previously described. 17 For bacterial experiments, penicillin-streptomycin was removed 48 h before. ALMs were passaged every 5-7 days at a ratio of 1:10 using ReLeSR. Details of all reagents are reported in Table S1 .

Animal experiments were completed in compliance with the Animal Care Committee at The Hospital for Sick Children (AUP #46059 and #59356). Adult male C57BL6/J mice and Sprague-Dawley rats were sacrificed with pentobarbitol. The thoracic cavity was opened and a tracheostomy was performed, then the lungs were instilled with Dulbecco's phosphate-buffered saline (DPBS), and bronchoalveolar lavage fluid (BALF) was collected. For mice, lungs were lavaged with a 24-gauge angiocath with 3 × 1 ml DPBS. For rats, lungs were lavaged with a 20-gauge angiocath with 3 × 10 ml DPBS. Each aliquot was used to lavage the lungs twice. BALF collected was centrifuged at 400g for 20 min. The pellet was resuspended in macrophage media, transferred to tissue culture plates and incubated. Primary 

1'AMs and ALMs were cultured at the same density in macrophage media. Cells were imaged using the same x/y coordinates at ×100 magnification on Days 0-7 using a light microscope (Leica DMI300B) and Volocity software (Perkin Elmer Inc, Version 6.3).

The number of cells per field of view was manually counted.

Mouse ALMs were previously characterized for known 1'AM markers. 17 Here, we further characterized mouse ALMs and 1'AMs for their expression of toll-like receptor (TLR) 2, 4 and 5. Rat ALMs and 1'AMs were characterized using known 1'AM cell surface markers; CD45, 19 SIRPα, 19 CD11b/c 20 and mature macrophage marker, 21 along with TLR2, 4 and 5. Briefly, 1'AMs and ALMs were collected and the FcϒII receptor was blocked with anti-CD32 for 5 min. All antibodies were added for 30 min. Further details are outlined in Table S2 or previously described. 17 A Gallios 10/3 flow cytometer (Beckman-Coulter) was used for acquisition and data were analysed using Kaluza software (Beckman-Coulter). Inc), using Metamorph software (Molecular Devices). Image processing, including iterative restoration (confidence limit = 99%, 10 iteration limit = 10) was completed using Volocity. Live cell imaging of mouse ALMs cultured with E.C. and rat ALMs cultured E.C. and P.A., with was completed using a Leica CTRMIC 6000 confocal microscope as previously described. 17 

To perform a gentamicin protection assay (GPA), ALMs were sus- 

Mice and rats were anaesthetized with a loading dose of ketamine (mice 20 mg/kg, rat 75 mg/kg) and xylazine (mice 10 mg/kg, rat 25 mg/kg), followed by a 2 min exposure to 2% isofluorane. Four million mouse ALMs or 1 × 10 7 rat ALMs were instilled intratracheally into the lungs via either a 24-or 20-gauge angiocath. Mice ALMs expressed DsRed for tracking. 17 Rat ALMs were prestained with CellTrace™ for tracking. Following 24 h, BALF was collected and the viability of ALMs was determined by flow cytometry using cell viability VivaFix assay. Proliferation of ALMs was determined by flow cytometry using an anti-Ki67 antibody. Further antibody details are in Table S2 . Flow cytometry results were gated using the DsRed and CellTrace™ dye fluorescence to distinguish the administered ALMs from primary BALF cells.

Mice and rats were anaesthetized and 4 × 10 6 DsRed-expressing ALMs or 10 × 10 6 CellTrace™-expressing ALMs, respectively, were instilled. Following 72 h, BALF was collected as described above. Table S2 .

Live GFP-expressing E.C. and P.A., mouse DsRed ALMs and rat CellTrace™ ALMs were prepared as described above. For mice, 1 × 10 7 bacteria were instilled while rats were instilled with 1 × 10 8 bacteria. ALMs were instilled 30 min after the initial bacterial instillation to achieve a MOI of 10:1 for bacteria:ALMs (mice: 1 × 10 6

ALMs, rats: 1 × 10 7 ALMs).

| Internalization of E. coli and P. aeruginosa by rat and mouse alveolar-like macrophages BALF was collected 3 h post-instillation. Flow cytometry was performed on BALF, gating for GFP (bacteria) and DsRed or CellTrace™.

Mouse GFP + DsRed + and rat GFP + CellTrace™ + cells were considered ALMs that had internalized bacteria. Internalization was confirmed by creating cytospots and ensuring co-localization of GFP and DsRed or CellTrace™ staining. For cytospots, 1 × 10 5 ALMs were adhered to slides at 300g and fixed with 4% (v/v) PFA for 20 min.

Mouse GFP + DsRed + ALMs were imaged on a Leica DM 6000B microscope connected to a Leica TCS SP5 system using Leica Application Suite Advanced Fluorescence software (version 1.6.0) (Leica Microsystems Inc). GFP + CellTrace™ + ALMs were imaged using confocal microscopy and analysed as outlined above. Figure S1 provides a schematic experimental workflow.

To assess rat ALMs ability to kill P.A. from the lysis step onwards as described above. Bacterial load (BALF supernatant) and survival (ALMs and primary BALF cells) were calculated as described above using the T0 and T24 time points. Figure S2 provides a schematic experimental workflow. This experiment was not performed in mice as a significant number of cells need to be recovered for FACS, therefore requiring a large number of mice to be used that could not ethically be justified.

To determine the role of ALMs in P.A.-induced lung injury, 1 × 10 8 PA01 was intratracheally instilled into rats, with controls receiving DPBS. Six hours later, both groups were instilled with either 1 × 10 7 ALMs or a DPBS control. Rats were weighed daily for seven days. At Day 7 the right lung was collected to determine the wet/ dry weight ratio and the left lung was pressure fixed at 20 cm H 2 O with 4% (v/v) PFA and the tissue was processed through a number of ethanol, xylazine and wax baths before being embedded. Three 5 μm sections were cut 100 μm apart and stained with haematoxylin and eosin. From each section, 20 images were randomly taken in a grid-like fashion with a ×200 magnification on a light microscope and Volocity as described above. An injury score was assigned to each image based on the presence and severity of epithelial thickening, epithelial sloughing, oedema and infiltrate. Each parameter was scored out of two with a final score out of eight. Three researchers independently scored 60 images per rat in a doubleblinded fashion, and an average score was taken per rat from all three researchers. Figure S3 provides a schematic experimental workflow.

Data are presented as mean ± SEM. Comparisons between groups were made using paired Student's t-test using Welch's correction where appropriate. Where multiple comparisons were required, either a one-way, two-way or repeated-measures ANOVA was used with either a Sidak or Tukey post hoc test. Statistical significance was set at p < 0.05. Statistical analysis and graphing were performed using GraphPad Prism 6.

The proliferative capabilities of ALMs and 1'AMs were directly compared. The doubling rate of rat and mice ALMs was 34.20 ± 1.25 and 46.40 ± 1.73 h, respectively, while 1'AMs did not divide, and the number of 1'AMs even decreased over seven days ( Figure 1A and B).

The experiment was terminated at seven days as the ALMs overgrow the culture dish at this point, but after passaging they continue to proliferate and can be continuously cultured in vitro for at least two years without a reduction in growth rate. 17 

Rat ALMs and 1'AMs were compared for their surface marker expression ( Figure S4A , n = 5). The rat ALM population highly expressed the 1'AM markers SIRPα, CD11b/c, mature macrophage marker, however, did not express the pan myeloid marker CD45, and CD86. Rat 1'AMs highly expressed CD45 and SIRPα, however, did not express the mature macrophage marker, CD11b/c or CD86.

Mouse ALMs and 1'AMs expressed F4/80, CD11c, Siglec F, CD24, CD80, CD86 and CD206 but did not express MHCII or Langerin.

CD64 was expressed on mouse ALMs but not on 1'AMs 17 ( Figure   S4B , n = 5). 

ALMs and 1'AMs were analysed for surface markers TLR2, TLR4 and TLR5. Mouse ALMs and 1'AMs highly express TLR2 and co-express TLR4 and TLR5 ( Figure 1C , n = 3-5). Rat ALMs highly express TLR2 and co-expresses TLR4 and TLR5 whereas the rat 1'AM population highly express TLR2 and TLR5 but not TLR4 ( Figure 1D , n = 3-5).

Scanning electron micrographs demonstrated P.A. associating with mouse ALMs (Figure 2A ). Pseudopodia extend from the surface of the ALM and wrap around a P.A., followed by formation in the phagocytic cup before beginning to envelope a P.A. Confocal imaging confirmed that mouse ALMs ( Figure 2B ) and rat ALMs ( Figure 2C) internalize live E.C. and P.A and retain them in vacuolar structures resembling phagosomes. Figure 3B ). Reinterpretation of this data illustrated that mouse and rat ALMs display similar bactericidal efficiencies to P.A. (Figure S5A ).

Ten strains of P.A. were obtained from clinical isolates of CF patient sputum samples whose eradication status towards tobramycin treatment had been previously determined ( Figure S5B ). ALMs displayed bactericidal activity to all P.A. patient strains (representative examples in Figure 3C and D). The killing capacity of mouse ALMs was significantly increased (from 0% at T0) in response to the eradicated strains PA288 (58.82 ± 4.89%, p = 0.0003, n = 5) and PA558 (78.17 ± 9.17%, p = 0.0135, n = 3) and the persistent strains PA342 (85.54 ± 4.59%, p = 0.0029, n = 3) and PA580 (92.14 ± 3.31%, p = 0.0013, n = 3). The killing capacity of rat ALMs was significantly increased (from 0% at T0) in response to the eradicated strains PA288 (79.94 ± 2.07%, p = 0.0007, n = 3) and PA558 (65.49 ± 5.20%, p = 0.0002, n = 5) and the persistent strains PA342 (66.20 ± 4.67%, p = 0.0008, n = 5) and PA580 (96.96 ± 1.19%, p = 0.0001, n = 5).

Re-interpretation of this data illustrated that mouse and rat ALMs display similar bactericidal efficiencies to both laboratory and clinical strains of P.A. (Figure S5C ).

Twenty-four hours post-instillation, mouse ALMs retained 93.57 ± 0.39% (n = 3) and 60.73 ± 6.32% (n = 3), respectively, of their viability and proliferative capacity compared with 97.33 ± 1.33% 

In mice and rats, three days post-ALM administration the expres- 

Firstly, we established that mouse ALMs could internalize E.C. and P.A. in vivo over 3 h; 15.88 ± 4.48% and 31.83 ± 3.54% (n = 3) of mouse ALMs internalize E.C. and P.A., respectively ( Figure 5A and B) .

Also 57.74 ± 3.71% (n = 3) of rat ALMs internalize P.A. ( Figure 5C ).

Next, we assessed the ability of rat ALMs and primary BALF cells 

Body weight was measured daily for seven days post-instillation.

Differences were observed between groups (p group = 0.0645, Figure S6 ).

Bactericidal capacity of alveolar-like macrophages to kill P. aeruginosa, E. coli, S. aureus and clinical respiratory strains of P. aeruginosa in vitro. Bacterial percentage killing for mouse (A) and rat (B) ALMs targeting live laboratory strains of E.C., P.A. and S.A. were determined using a GPA. Bacterial per cent killing for mouse (C) and rat (D) ALMs targeting various clinical P.A. strains that are either tobramycin sensitive and are eradicated by antibiotics (ER) or are resistant to tobramycin and persist with antibiotic treatment (PR) were determined using a GPA. Data in all panels are presented as mean ± SEM, n = 3-5 separate experiments each with technical triplicates. Statistical comparisons were made against the T0 time point (data not shown)

Recently, the need to establish more effective therapeutic approaches towards lung diseases and infections has driven the development of cell-based therapies. 24, 25 This rapidly evolving area led to the development of ALMs, 17 Surface expression of known 1'AM markers 20,21,26 was confirmed on rat ALMs establishing their similarity to 1'AMs. Rat ALMs similarly express CD86 and SIRPα; however, CD11b/c and the mature macrophage marker are highly expressed in rat ALMs compared to 1'AMs. 17 This differential expression could be due to variable activation states of in vitro ALMs and in vivo 1'AMs, which is known to alter marker expression. 20 CD45 is expressed by virtually all hematopoietic cells; however, some primitive macrophage subsets, such as microglia and those derived from yolk-sac haematopoiesis express low or no CD45. 27 Interestingly, mouse ALMs express CD45 but rat ALMs do not, suggesting that the expression of CD45 on ALMs is non-essential to their characteristics and function in general and re-affirming that ALMs retain a primitive signature. 17,28 Importantly, mouse and rat ALMs express TLRs 2, 4 and 5, known to be responsive to the pathogen-associated molecular patterns of LPS and flagellin 29, 30 ; and ALMs proliferate more sustainably and rapidly than 1'AMs and primary bone marrow-derived macrophages. 17 Mouse 1'AMs have been cultured to 20 passages in vitro, 15, 31 and human iPSC-derived macrophages have been harvested for up to three months post-differentiation in a bioreactor system 32 ; however, the rate of proliferation of our F I G U R E 4 Alveolar-like macrophages are viable but have reduced proliferative capacity in vivo. Mouse DsRed + ALMs (A) and rat CellTrace™ + ALMs (B) are viable and proliferative, when cultured to 50% confluency in vitro prior to instillation. 24 h post in vivo instillation ALMs were collected via bronchoalveolar lavage fluid (BALF). The mouse DsRed + ALM or rat CellTrace™ + ALM population in the BALF was separated from endogenous populations by flow cytometry. Mouse and rat ALMs retain their viability, but their proliferative capacity is diminished. Data in both panels are presented as mean ± SEM. Black histograms; unstained control cells, white histograms; stained cells. ESC-derived ALMs is significantly greater and they remain proliferative over longer periods of time. 17 ALMs are therefore easily scalable to therapeutic numbers, which is key to producing a cost and time effective cell-based therapy.

One of the major effector functions of 1'AMs is their ability to phagocytose and kill pathogens. 33 Thus, we determined the bactericidal effects of ALMs. After visualizing bacterial internalization, we confirmed that both rat and mouse ALMs effectively kill laboratory strains of E.C., P.A. and S.A. with greater than 70% killing efficiency. Moreover, ALMs efficiently kill clinical strains of P.A. It is important to recognize that ALMs effectively killed both eradicated and persistent P.A. clinical strains with the same efficiency as F I G U R E 5 Alveolar-like macrophages display bactericidal effects in vivo by internalizing P. aeruginosa and E. coli. Adult mice and rats were infected intratracheally with either live GFPexpressing E.C. and/or P.A. Thirty minutes post-infection, mice and rats were instilled intratracheally with mouse DsRed + ALMs or rat CellTrace™ + ALMs, respectively. Three hours following the initial infection mice and rats were sacrificed and BALF cells were collected. In the present study, we also characterized ALMs in vivo and demonstrated that ALMs remain viable (~95%) but drop their proliferation rate by ~50%, suggesting ALMs adapt to the lung niche and present as 1'AMs, which exhibit slow proliferation rates in vivo. 34 This reduction in proliferation could be beneficial, as it suggests

ALMs are less likely to become tumorigenic, an important distinction as ALMs can be retained in the airways for at least 4 weeks. 17 In mice, ALM polarization towards a M1 or M2 phenotype was not observed; however, we observed that ALMs adapt to the lung niche by reducing their expression of CD86 and CD206, and increasing their expression of Siglec-F to adopt a phenotype more analogous to 1'AMs. We also observed a marginal increase in the CD11b + /GR-1 + neutrophil population in the BALF following ALM administration in mice. This increase from ~2% to ~8% is unlikely to indicate an acute inflammatory response as >90% neutrophils are observed in the BALF of inflammatory LPS models. 35, 36 Unlike mice, rat ALMs exhibit a distinctly M2 phenotype, both in vitro and three days postinstillation in rat lungs. After transplantation, rat ALMs also adopt a phenotype similar to 1'AMs, as seen with a reduction in CD206 expression to 1'AM levels. it is plausible that the bacterial load may be reduced or resolved at a later time point, especially as the amelioration of weight loss was observed from Day 4 onwards. However, another mechanism for the ALM-driven resolution of lung injury could be rat ALMs maintaining a predominant M2 phenotype within the lung microenvironment. It is F I G U R E 7 Alveolar-like macrophages resolve P. aeruginosa-induced lung injury in vivo. Adult rats were infected intratracheally with P.A. or DPBS. Six hours post-instillation, rats were instilled intratracheally with either ALMs or DPBS. Rats were weighed daily, and histological analysis was performed at Day 7 postinstillation. (A) Rats in the PA01 + DPBS group was lighter than the DPBS + DPBS and DPBS + ALM groups by Day 4 and all three experimental groups by Day 5 onwards. Data are mean ± SEM, n = 3-4 rats per experimental group. Statistically significant difference; * denotes p < 0.05 between experimental groups in a Tukey's post hoc test. Data were expressed as a percentage gain in body weight to normalize for the variable starting weights (pre-instillation). (B) Lung histological analysis demonstrated that the injury score was significantly greater in the PA01 + DPBS group compared to the other three experimental groups, with no differences observed between the other groups. Data are mean ± SEM, n = 3-4 rats per experimental group. Experimental groups with different letters (above the bar) are significantly different from each other. (C-F) Representative histological images of DPBS + DPBS, DPBS + ALM, PA01 + DPBS and PA01 + ALM groups, respectively. Images were taken at ×200 magnification. Scale bars are 50 μm. Images are representative of 3-4 rats per experimental group probable that M2 ALMs can downregulate the magnitude and longevity of neutrophil influx and aid in efferocytosis, a known M2 macrophage effector function, 40 resulting in the mitigation of P.A.-induced structural lung injury and weight loss by Day 7. Future studies will be more expansive, including determining the bacterial load and cytokine profiles at different time points and whether greater ALM dosages can reduce the bacterial load even after 24 h.

Together, these data are the first to show ALM-driven resolution of P.A.-induced lung injury, and further supports the concept of ALMs promoting airway repair in disease models. 17 Recently, it has been reported that murine hematopoietic stem cell transplantation 39 or delivery of human iPSC-derived macrophages 32 rescued mice from P.A. airway infection; however, the critical distinction is that these graft-derived or instilled macrophages were of bone marrow or non-primitive origins, unlike ALMs that are engineered to reside in the lung for long periods of time. Moreover, in these studies the graft-derived macrophages already resided in the lung prior to infection 39 while human iPSC-derived macrophages were instilled at the time of infection. 32 In contrast, in our study ALMs were delivered post-infection, which more realistically mimics a clinical time-course.

Collectively, the use of ALMs as a translational cell-based bactericidal therapy holds great promise in future. ALMs are a robust proliferative cell with the potential to be utilized as an alternative or adjuvant therapy where current strategies are ineffective against antibiotic-resistant bacteria or to enhance routine antibiotic delivery. Importantly, ALMs not only resolve lung injury but also are effective antibacterial cells that attenuate pulmonary bacterial infection and promote repair. Moreover, ALMs scalability and immunological functionality make them versatile cells that are permissible to transfection and thus could be altered to further enhance their bactericidal and immunoregulatory functions and be used as a platform to treat a multitude of lung diseases.

Litvack: Conceptualization (equal); data curation (equal); formal analysis (equal); funding acquisition (supporting)

methodology (equal); project administration (equal); writing -original draft (supporting); writing -review & editing (equal)

Data curation (supporting); formal analysis (supporting)

Data curation (supporting); formal analysis (supporting)

Amber J. Park: Data curation (supporting); formal analysis (supporting). Elyse J. Roach: Data curation (supporting)

Berezuk: Data curation (supporting)

Cezar M. Khursigara: Data curation (supporting); formal analysis (supporting); supervision (supporting)

Conceptualization (equal); formal analysis (supporting); funding acquisition (lead); investigation (equal); methodology (equal); project administration (equal); resources (equal); supervision (lead)

The global burden of respiratory disease

Respiratory bacterial infections in cystic fibrosis

Common infections in the lung transplant recipient

Lung infections in the HIV-infected adult

Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms

Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

New opportunities for managing acute and chronic lung infections

Antimicrobial resistance and covid-19: intersections and implications

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

A global priority list of the TOp TEn resistant microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis

Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF

Alveolar macrophage in the driver's seat

A lineage of myeloid cells independent of myb and hematopoietic stem cells

Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cells

Alveolar macrophages

Alveolar-like stem cell-derived myb(-) macrophages promote recovery and survival in airway disease

Alveolar-like macrophages attenuate respiratory syncytial virus infection

Signal-regulatory protein is selectively expressed by myeloid and neuronal cells

Flow cytometric analysis of the leukocyte landscape during bleomycin-induced lung injury and fibrosis in the rat

Gene network analysis of interstitial macrophages after treatment with induced pluripotent stem cells secretome (iPSC-cm) in the bleomycin injured rat lung

Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms

Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals

Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia

Stem cell therapy for COPD: hope and exploitation

Phenotypical and functional characterization of alveolar macrophage subpopulations in the lungs of NO 2 -exposed rats

Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors

Embryonic-derived myb− macrophages enhance bacterial clearance and improve survival in rat sepsis

Macrophage TLR4 and PAR2 signaling: role in regulating vascular inflammatory injury and repair

TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury

Cultivation of mouse alveolar macrophages

Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections

Origin and ontogeny of lung macrophages: from mice to humans

Alveolar macrophage dynamics in murine lung regeneration

Intranasal administration of poly(I:C) and LPS in BALB/C mice induces airway hyperresponsiveness and inflammation via different pathways

Neutrophil GM-CSF receptor dynamics in acute lung injury

Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia

Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway

Rescue from Pseudomonas aeruginosa airway infection via stem cell transplantation

Ex vivo and in vitro effect of serum amyloid A in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils

The authors wish to thank the Dr Lynne Howell laboratory at The Hospital for Sick Children, Canada, for their generous donation of P.A. PA01 (lab strain) and Dr Valerie Waters laboratory at The Hospital for Sick Children, Canada, for their donation of clinical strains of P.A. All schematic methodology images were created with BioRender.com.

The authors confirm that there are no conflicts of interest.

Sheena Bouch:Conceptualization (equal); data curation (lead); formal analysis (lead); funding acquisition (supporting); investigation (equal); methodology (equal); project administration (equal); writing -original draft (lead); writing -review & editing (equal). Michael L.

Additional supporting information may be found in the online version of the article at the publisher's website.